<DOC>
	<DOC>NCT02781584</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and tolerability of selonsertib (GS-4997), GS-0976, and GS-9674 in adults with nonalcoholic steatohepatitis (NASH).</brief_summary>
	<brief_title>Safety, Tolerability, and Efficacy of Selonsertib, GS-0976, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)</brief_title>
	<detailed_description />
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Key Males and females between 1875 years of age; inclusive based on the date of the screening visit Willing and able to provide informed consent prior to any study specific procedures being performed Meets the following conditions: Clinical diagnosis of nonalcoholic fatty liver disease, screening FibroTest® &lt; 0.75, unless a historical liver biopsy within 12 months of screening does not reveal cirrhosis, screening magnetic resonance imaging proton density fat fraction (MRIPDFF) with ≥ 10% steatosis, and screening magnetic resonance elastography (MRE) with liver stiffness ≥ 2.88 kPa OR A historical liver biopsy within 12 months of screening consistent with NASH (defined as the presence of steatosis, inflammation, and ballooning) with stage 23 fibrosis according to the NASH Clinical Research Network (CRN) classification (or equivalent) and no documented weight loss &gt; 5% between the date of the liver biopsy and screening Key Pregnant or lactating females Other causes of liver disease including autoimmune, viral, and alcoholic liver disease Cirrhosis of the liver Any history of decompensated liver disease, including ascites, hepatic encephalopathy or variceal bleeding History of liver transplantation Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>